Table 3: Meta-analysis of psychchometric outcomes between rifaximin and nonabsorbable disaccharides.

Psychometric outcomesRifaximinControl Mean difference IV, random, 95% CI
MeanSDTotalMeanSDTotal

Mental status

Bucci and Palmieri 1993 [26]0.80.5301.20.328−0.40 [−0.61, −0.19]
Loguercio et al. 2003 [29]0.420.67140.90.7413−0.48 [−1.01, 0.05]
Massa et al. 1993 [27]0.60.2201.20.320−0.60 [−0.76, −0.44]
Paik et al. 2005 [21]0.50.7320.30.4220.2 [−0.09, 0.49]

Total (95% CI)9683−0.32 [−0.67, 0.03]

Heterogeneity: = 0.10; = 22.09; df = 3 ( < 0.0001); = 86%
Test for overall effect: = 1.80 ( = 0.07)

Asterixis

Bucci and Palmieri 1993 [26]0.50.3301.20.328−0.40 [−0.61, −0.19]
Mas et al. 2003 [28]00.55000.5530.00 [−0.19, 0.19]
Massa et al. 1993 [27]0.10.2200.10.2200.00 [−0.12, 0.12]
Paik et al. 2005 [21]0.30.7320.40.622−0.10 [−0.45, 0.25]

Total (95% CI)132123−0.12 [−0.31, 0.08]

Heterogeneity: = 0.03; = 10.85; df = 3 ( = 0.01); = 72%
Test for overall effect: = 1.19 ( = 0.23)

EEG

Bucci and Palmieri 1993 [26]0.40.2300.60.328−0.20 [−0.33, −0.07]
Mas et al. 2003 [28]0.60.9500.90.953−0.30 [−0.65, 0.05]

Total (95% CI)8081−0.21 [−0.34, −0.09]

Heterogeneity: = 0.00; = 0.28; df = 1 ( = 0.60); = 0%
Test for overall effect: = 3.37 ( = 0.0007)

PSE sum

Mas et al. 2003 [28]40.1506253−2.00 [−2.54, −1.46]
Massa et al. 1993 [27]30.5205.50.520−2.50 [−2.78, −1.82]

Total (95% CI)7073−2.30 [−2.78, −1.82]

Heterogeneity: = 0.07; = 2.48; df = 1 ( = 0.12); = 60%
Test for overall effect: = 9.40 ( < 0.00001)

IV: inverse variance, EEG: electroencephalogram, and PSE: portosystemic encephalopathy.